Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

64.26 +0.81 (+1.28%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biomarin Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9 Next >
When you look at NASDAQ:BMRN, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
In a market where value is scarce, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
Can BioMarin Stock Live Up to Wall Street’s High Expectations?
BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon? 
Via MarketBeat
The Analyst Landscape: 29 Takes On Biomarin Pharmaceutical
Via Benzinga
NASDAQ:BMRN stands out as a growth opportunity that won't break the bank.
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) is showing decent growth, but is still valued reasonably. 
Via Chartmill
Peering Into Biomarin Pharmaceutical's Recent Short Interest
Via Benzinga
CAMP4 Analyst Highlights Rare Disease Platform Potential
CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts project $1 billion in revenue for UCD drug by 2036. 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
In-Depth Examination Of 29 Analyst Recommendations For Biomarin Pharmaceutical
Via Benzinga
A Look Ahead: Biomarin Pharmaceutical's Earnings Forecast
Via Benzinga
Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN.
NASDAQ:BMRN is showing good growth, while it is not too expensive. 
Via Chartmill
BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth
BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong Voxzogo growth. Analyst downgrades on lack of upcoming catalysts. 
Via Benzinga
NASDAQ:BMRN appears to be flying under the radar despite its strong fundamentals.
Investors should take notice ofBIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
How Is The Market Feeling About Biomarin Pharmaceutical?
Via Benzinga
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential... 
Via Benzinga
Analyst Expectations For Biomarin Pharmaceutical's Future
Via Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $14,000 Today
Via Benzinga
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
Via Benzinga
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
Via Benzinga
Investors should take note of NASDAQ:BMRN, a growth stock that remains attractively priced.
Despite its growth, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) remains within the realm of affordability. 
Via Chartmill
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish
BioMarin Pharmaceutical aims to achieve $4 billion in revenue by 2027, driven by Voxzogo adoption, despite emerging competition from Ascendis Pharma. Goldman Sachs maintains a "Buy" rating with a $139... 
Via Benzinga
Investors should take notice of NASDAQ:BMRN—it offers a great deal for the fundamentals it presents.
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), an undervalued stock with good fundamentals. 
Via Chartmill
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90% 
Via Benzinga
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by late 2025 due to its dosing schedule and potential safety benefits. 
Via Benzinga
Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug
The companies could soon face off in the growth treatment market for children with a genetic disorder. 
Via Investor's Business Daily
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked. 
Via Benzinga
Exposures Product Safety
BioMarin Restructures, Outlines Roadmap To $4B Revenues By 2027
BioMarin aims for $4 billion revenue by 2027, focusing on gene therapy and enzyme treatments, with a robust pipeline set to enhance growth. 
Via Benzinga
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (14 Ratings)
Via Benzinga
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included a higher-than-expected U.S. price for Yorvipath and a delayed cash flow... 
Via Benzinga
NASDAQ:BMRN is showing good growth, while it is not too expensive.
Investors should take note ofBIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), a growth stock that remains attractively priced. 
Via Chartmill
Wall Street's Top 10 Stock Calls This Week - Saturday, Aug. 24
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Aug. 19-23, 2024. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback